| abstract |
FIELD: medicine, biochemistry, nucleic acids. SUBSTANCE: invention relates to the purified and isolated RNA-ligands no occurring in nature to vesical endothelial growth factor (VEGF) where oligonucleotide sequences are indicated. Invention describes complexes of the formula A-B-Y where A means polyalkyl ne glycol or glycerol lipid; B means linker(s); Y means RNA-ligand to VEGF. Invention describes method of synthesis of these complexes including identification of RNA-ligand from a mixture of nucleic acid candidates eliciting the enhanced affinity to VEGF and lipid structure including this complex. Complexes improve pharmacokinetic properties of RNA-ligands to VEGF and used for treatment of patients with VEGF-mediated diseases, among them, for inhibition of VEGF- mediated angiogenesis, tumors growth and degeneration of yellow spot. Invention proposes also method of clearance decrease of nucleic acid-ligand to VEGF from plasma, method of prolongation of its effect in eye and method of direction of therapeutic or diagnostic agent to biological target. EFFECT: valuable properties of complexes. 77 cl, 34 dwg, 13 tbl, 11 ex |